{"id":47413,"date":"2022-08-17T22:02:08","date_gmt":"2022-08-17T20:02:08","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/exscientia-business-update-for-second-quarter-and-first-half-2022\/"},"modified":"2022-08-17T22:02:08","modified_gmt":"2022-08-17T20:02:08","slug":"exscientia-business-update-for-second-quarter-and-first-half-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/exscientia-business-update-for-second-quarter-and-first-half-2022\/","title":{"rendered":"Exscientia Business Update for Second Quarter and First Half 2022"},"content":{"rendered":"<div>\n<p>OXFORD, England&#8211;(BUSINESS WIRE)&#8211;Exscientia plc (Nasdaq: EXAI)\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220817005681\/en\/1547256\/1\/1H_2022_1pager_final2.pdf\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220817005681\/en\/1547256\/21\/1H_2022_1pager_final2.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20220817005681\/en\/1547257\/5\/Exscientia_Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220817005681\/en\/1547257\/21\/Exscientia_Logo.jpg\"><\/a><\/p>\n<p>\nRecent developments in the Company\u2019s pipeline, collaborations, and operations, as well as financial results for the second quarter and first half 2022, are summarised below. In addition, Exscientia will host a <b>conference call Thursday, August 18 at 1:30 p.m. BST<\/b> \/ <b>8:30 a.m. ET <\/b>to provide an overview of the company\u2019s pipeline and corporate strategy.\n<\/p>\n<p>\n\u201cIn the first half of 2022, we delivered on major new and existing collaborations, advanced our pipeline programmes, and marked the 10-year anniversary of Exscientia\u2019s founding. Over the past decade, we\u2019ve pioneered an AI-driven approach to modernising drug discovery and development, and it was fitting that this quarter we also announced topline data from our EXS-21546 programme, one of the first AI-designed molecules to enter clinical trials,\u201d said Andrew Hopkins, D.Phil., Exscientia&#8217;s founder and Chief Executive Officer. \u201cWith over $730 million in cash, we believe we are in a strong position to deliver across our portfolio of drug projects for the long-term. Our strategy creates an agile interplay between our internal pipeline and partnered programmes, enabling us to move candidates between the two depending on the best fit for Exscientia and our partners, as well as how we can best impact the probability of success for patients.\u201d\n<\/p>\n<p>\n<b>Recent Highlights<\/b>\n<\/p>\n<p>\nProgress across internal and partnered pipeline, leveraging the Company&#8217;s precision medicine platform, as well as key components of Exscientia&#8217;s technology and operations.\n<\/p>\n<p>\n<b>Internal pipeline<\/b>\n<\/p>\n<p>\n<b><i>Wholly, majority and co-owned programmes focused on areas in which Exscientia believes it can improve the probability of success, including precision oncology<\/i><\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nFollowing topline data in June, the Company remains on track to initiate a Phase 1b\/2 study of EXS-21546 (majority owned with Evotec) in the second half of 2022<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nPhase 1b\/2 study will be optimised with simulation-guided clinical trial design principles as well as leverage Exscientia&#8217;s precision medicine platform to maximise potential impact to the most relevant patients\n<\/li>\n<\/ul>\n<\/li>\n<li>\nGTAEXS-617 (co-owned with GT Apeiron) CTA submission expected by year-end 2022<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nCTA and IND-enabling studies are ongoing, including translational work to support planned clinical trials expected to start in the first half of 2023\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>\n<b>Partnered programmes<\/b>\n<\/p>\n<p>\n<b><i>Utilising a scalable end-to-end platform to advance a broad pipeline, while also generating significant cash inflows to support advancements<\/i><\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nFirst two targets identified in new Sanofi collaboration for oncology and inflammation &amp; immunity, respectively\n<\/li>\n<li>\nFirst precision medicine project initiated; focused on patient enrichment for a Sanofi biologic in oncology\n<\/li>\n<li>\nAdvancing Bristol Myers Squibb (BMS) collaboration with continued progress across both BMS1 and BMS2 collaborations\n<\/li>\n<li>\nFollowing the achievement of recent successful drug discovery milestone, Exscientia and Bayer have mutually agreed to end collaboration; Exscientia will retain optionality to develop one of the two targets pursued under the collaboration<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nThe Bayer agreement was the last Exscientia partnership based on AI-only design services, which included lower economics and reduced operational involvement in comparison with more recent partnerships\n<\/li>\n<li>\nThis update aligns with Company strategy to increasingly focus on programmes where Exscientia\u2019s AI design, experimental biology and precision medicine platforms can be integrated\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>\n<b>Recent clinical progress highlights ability of the Company\u2019s advanced, AI-based platform to create novel molecules with high level of translatability to human biology<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nAnnounced topline data from EXS-21546 Phase 1a healthy volunteer study in June 2022<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nThe study demonstrated that observed human pharmacokinetics for EXS-21546 were in line with what had been designed for and predicted in preclinical modelling, supporting a twice-daily (BID) dose for continuous A<sub>2A<\/sub> receptor inhibition over a dosing interval\n<\/li>\n<li>\nEXS-21546 signalled inhibition of A<sub>2A<\/sub> receptor was sustained over the BID dosing period, demonstrating a level of lasting target engagement\n<\/li>\n<li>\nEXS-21546 was well-tolerated with no CNS adverse events reported in the SAD portion at all doses (30mg, 90mg, 250mg, 400mg) and in the MAD portion at 150mg BID\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>\n<b>Exscientia&#8217;s approach allows for significant cash inflows to drive the business<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n$111.0 million cash flow from collaborations in second quarter 2022, including $100.0 million from Sanofi, ending the first half 2022 with $732.0 million in cash, cash equivalents and short-term bank deposits<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nIncludes constant currency mark-to-market foreign exchange impact of negative 8%\n<\/li>\n<li>\nDuring the quarter, Exscientia recognised realised foreign exchange gains net of forward contract settlements of $14.0 million. The Company holds its deposits in both GBP and USD intended to match expected cash needs while limiting the impact of exchange rate fluctuations\n<\/li>\n<\/ul>\n<\/li>\n<li>\nSecond quarter 2022 net positive cash inflows from operations of $72.9 million\n<\/li>\n<\/ul>\n<p>\n<b>Expanded leadership team in critical growth areas<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nEileen Jennings-Brown joined as Exscientia&#8217;s Chief Information Officer, reporting to Garry Pairaudeau, Chief Technology Officer, and responsible for overseeing IT and DevOps. Ms. Jennings-Brown brings more than 25 years of experience across IT roles, including most recently heading technology for the Wellcome Trust.\n<\/li>\n<li>\nCharlotte Deane, Ph.D., Chief Scientist of Biologics AI, who joined Exscientia in January 2022, was awarded an appointment to the Most Excellent Order of the British Empire (MBE) for leading the UK Research and Innovation&#8217;s rapid response call for projects addressing issues arising from the pandemic.\n<\/li>\n<\/ul>\n<p>\n<b>Select peer-reviewed publications and scientific meeting presentations during the quarter<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n\u201c<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fpubs.acs.org%2Fdoi%2F10.1021%2Facs.jcim.2c00258&amp;esheet=52817622&amp;newsitemid=20220817005681&amp;lan=en-US&amp;anchor=Coverage+Score%3A+A+Model+Agnostic+Method+to+Efficiently+Explore+Chemical+Space&amp;index=1&amp;md5=dd865a391812f5a62e8f040f0484bdf5\" rel=\"nofollow noopener\" shape=\"rect\">Coverage Score: A Model Agnostic Method to Efficiently Explore Chemical Space<\/a>,\u201d was published in the <i>Journal of Chemical Information and Modeling<\/i> in July 2022. This advancement in active learning allows more efficient exploration of chemical space, potentially leading to increased diversity of candidates, faster model improvement and shorter time to candidate identification\n<\/li>\n<li>\n\u201c<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fpubs.acs.org%2Fdoi%2F10.1021%2Facsmedchemlett.2c00099&amp;esheet=52817622&amp;newsitemid=20220817005681&amp;lan=en-US&amp;anchor=Surface+Plasmon+Resonance+Screening+to+Identify+Active+and+Selective+Adenosine+Receptor+Binding+Fragments&amp;index=2&amp;md5=b1940c067e31c46f37212f84399abb48\" rel=\"nofollow noopener\" shape=\"rect\">Surface Plasmon Resonance Screening to Identify Active and Selective Adenosine Receptor Binding Fragments<\/a>,\u201d a study which further validates Exscientia&#8217;s innovative biosensor approach to screening wildtype GPCR targets to advance drug discovery, was published in the <i>ACS Medicinal Chemistry Letters <\/i>in June 2022\n<\/li>\n<li>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.exscientia.ai%2Fpresentations-publications&amp;esheet=52817622&amp;newsitemid=20220817005681&amp;lan=en-US&amp;anchor=Three+posters&amp;index=3&amp;md5=4c2167d6271570fac2980feeb8180fad\" rel=\"nofollow noopener\" shape=\"rect\">Three posters<\/a> presented at the AACR Annual Meeting in April, highlighting Exscientia\u2019s human tissue precision medicine platform, including potential benefits of Exscientia\u2019s AI-driven design to overcome known issues such as potency, toxicity and selectivity and improve patient outcomes\n<\/li>\n<\/ul>\n<p>\n<b>Investor call and webcast information<\/b>\n<\/p>\n<p>\nExscientia will host a conference call on Thursday, August 18 at 1:30 p.m. BST \/ 8:30 a.m. ET. A webcast of the live call can be accessed by visiting the \u201cInvestors and Media\u201d section of the Company\u2019s website at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.exscientia.ai%2F&amp;esheet=52817622&amp;newsitemid=20220817005681&amp;lan=en-US&amp;anchor=investors.exscientia.ai&amp;index=4&amp;md5=ef07d737983ab2525be6a756cfc53b3c\" rel=\"nofollow noopener\" shape=\"rect\">investors.exscientia.ai<\/a>. Alternatively, the live conference call can be accessed by dialling +1 (888) 330 3292 (U.S.), +44 203 433 3846 (U.K.), +1 (646) 960 0857 (International) and entering the conference ID: 8333895. A replay will be available for 90 days under &#8220;Events and Presentations\u201d in the \u201cInvestors and Media\u201d section of the <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.exscientia.ai%2F&amp;esheet=52817622&amp;newsitemid=20220817005681&amp;lan=en-US&amp;anchor=Exscientia+website&amp;index=5&amp;md5=6a4d97f39d300809185b8be3d31bedd7\" rel=\"nofollow noopener\" shape=\"rect\">Exscientia website<\/a>.\n<\/p>\n<p>\n<b>Second quarter and first half 2022 financial results<\/b>\n<\/p>\n<p>\nFor the convenience of the reader, the Company has translated pound sterling amounts to U.S. dollars at the rate of \u00a31.000 to $1.2162, which was the noon buying rate of the Federal Reserve Bank of New York on June 30, 2022.\n<\/p>\n<p>\n<b>Revenue: <\/b>Recognised revenue for the three and six months ended June 30, 2022, was $8.7 million and $17.2 million respectively, representing an increase of $8.3 million and $10.4 million compared to the three and six months ended June 30, 2021, primarily due to delivery on an increased number of projects across our second collaboration with BMS, revenues generated from the extension of the BMS agreement to leverage Exscientia&#8217;s precision medicine platform, and recognition of remaining revenues following the termination of the Bayer agreement.\n<\/p>\n<p>\n<b>R&amp;D and cost of drug discovery: <\/b>Due to various collaboration structures, expenditure incurred in relation to research and development activities may be recognised within one of several financial statement captions. The tables below show how these expenses are separated across the accounting categories.\n<\/p>\n<p>\n<b><span class=\"bwuline\">Three months ended June 30, 2022 <\/span><\/b><i><span class=\"bwuline\">($ millions):<\/span><\/i><b>\u00a0<\/b>\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwpadr0 bwalignc bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>COGS\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwpadr0 bwalignc bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>R&amp;D\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwpadr0 bwalignc bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>Share of JV\u00a0<br \/>\n<br \/>loss\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwpadr0 bwalignc bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>Total\u00a0<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Partnered Programmes\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>10.9\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>\u2013\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>\u2013\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>10.9\u00a0<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Internal Pipeline and Technology Development\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>\u2013\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>40.2\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>0.3\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>40.5\u00a0<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Total\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>10.9\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>40.2\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>0.3\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>51.4\u00a0<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b><span class=\"bwuline\">Six months ended June 30, 2022 <\/span><\/b><i><span class=\"bwuline\">($ millions):<\/span><\/i>\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwpadr0 bwalignc bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>COGS\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwpadr0 bwalignc bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>R&amp;D\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwpadr0 bwalignc bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>Share of JV\u00a0<br \/>\n<br \/>loss\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwpadr0 bwalignc bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>Total\u00a0<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Partnered Programmes\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>17.7\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>\u2013\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>\u2013\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>17.7\u00a0<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Internal Pipeline and Technology Development\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>\u2013\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>68.8\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>0.7\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>69.5\u00a0<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Total\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>17.7\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>68.8\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>0.7\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>87.2\u00a0<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>Research and development expenses: <\/b>R&amp;D expenses for the three and six months ended June 30, 2022, were $40.2 million and $68.8 million respectively, as compared to $9.9 million and $15.1 million for the same period ended June 30, 2021. The increase in research and development expenses was in part due to the growth of Exscientia&#8217;s internal and co-owned portfolio, in addition to increased headcount and other costs associated with the Company&#8217;s continued technology investments. Share-based compensation accounted for $9.1 million and $12.1 million for the quarter and half year ended June 30, 2022, as compared to $1.6 million and $1.9 million for the same period ended June 30, 2021.\n<\/p>\n<p>\n<b>General and administrative expenses: <\/b>G&amp;A expenses for the three and six months ended June 30, 2022, were $14.7 million and $24.2 million respectively, or 22.3% and 21.9% respectively of total operating expenses. For the three and six months ended June 30, 2022, G&amp;A expenses increased by $5.6 million and $11.1 million compared to the three and six months ended June 30, 2021, primarily associated with an increase in personnel costs and additional costs incurred in relation to the operation of a listed company. Share-based compensation accounted for $3.3 million and $4.6 million for the quarter and half year ended June 30, 2022, as compared to $1.7 million and $2.0 million for the same periods ended June 30, 2021.\n<\/p>\n<p>\n<b>Cash inflows:<\/b> For the second quarter 2022, Exscientia received $111.0 million in cash inflows from its collaborations as compared to $39.5 million during the second quarter 2021.\n<\/p>\n<p>\n<b>Cash, cash equivalents and bank deposit<\/b><b>s:<\/b> Cash, cash equivalents and bank deposits as of June 30, 2022, were $732.0 million as compared to $683.7 million as of December 31, 2022. This includes a 12-month fixed term deposit of $121.7 million.\n<\/p>\n<p>\n<b>SELECTED CONSOLIDATED STATEMENT OF OPERATIONS, CONSTANT CURRENCY CONVERSION (unaudited)<\/b>\n<\/p>\n<p>\n(<i>$ millions, except per share data, at the rate of \u00a31.000 to $1.2162)<\/i>\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwpadr0 bwalignc bwpadl1\" colspan=\"2\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>Three months ended\u00a0<br \/>\n<br \/>June 30,\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwpadr0 bwalignc bwpadl1\" colspan=\"2\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>Six months ended\u00a0<br \/>\n<br \/>June 30,\u00a0<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwvertalignb bwalignc bwrowaltcolor1 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>2022\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwvertalignb bwalignc bwrowaltcolor1 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>2021\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwrightsingle bwpadr0 bwalignc bwrowaltcolor1 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>2022\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwrightsingle bwpadr0 bwalignc bwrowaltcolor1 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>2021\u00a0<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Revenue<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>8.7\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>0.4\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>17.2\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>6.8\u00a0<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCost of sales\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(10.9)\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(4.4)\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(17.7)\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(9.1)\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nResearch and development expenses\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(40.2)\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(10.0)\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(68.8)\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(15.1)\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nGeneral and administrative expenses\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(14.7)\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(9.1)\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(24.2)\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(13.1)\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Operating expenses<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(65.8)\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(23.5)\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(110.7)\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(37.3)\u00a0<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nForeign exchange gains\/(losses)\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n27.7\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(3.4)\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n39.5\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(3.5)\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nLoss on forward contracts\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(13.7)\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n&#8211;\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(13.7)\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n&#8211;\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nOther income\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n1.9\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n1.0\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n3.6\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n1.5\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Operating loss<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(41.2)\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(25.5)\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(64.1)\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(32.5)\u00a0<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nFinance income\/(expense)\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n0.4\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n&#8211;\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n0.5\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(0.1)\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nShare of loss on joint ventures\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(0.3)\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(0.5)\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(0.7)\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(0.9)\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nGain on derivative financial instrument\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n0.0\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n1.7\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n&#8211;\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n1.7\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Loss before taxation<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(41.1)\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(24.3)\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(64.3)\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(31.8)\u00a0<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nIncome tax benefit\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n6.3\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n1.7\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n10.6\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n2.6\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Loss for the period<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(34.8)\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(22.6)\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(53.7)\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(29.2)\u00a0<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Net loss per share<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(0.29)\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(0.86)\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(0.44)\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(1.02)\u00a0<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>SELECTED CONSOLIDATED BALANCE SHEET, CONSTANT CURRENCY CONVERSION (unaudited)<\/b>\n<\/p>\n<p>\n(<i>$ millions, except per share data, at the rate of \u00a31.000 to $1.2162)<\/i>\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignb bwsinglebottom bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwpadr0 bwalignc bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>June 30, 2022\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwpadr0 bwalignc bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>December 31, 2021\u00a0<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCash, cash equivalents &amp; short-term bank deposits\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n732.0\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n683.7\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Total assets<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>849.0\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>779.2\u00a0<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTotal equity\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n650.8\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n689.4\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTotal liabilities\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n198.2\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n89.8\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Total equity and liabilities<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>849.0\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>779.2\u00a0<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>SELECTED CONSOLIDATED STATEMENT OF CASH FLOWS. CONSTANT CURRENCY CONVERSION (unaudited)<\/b>\n<\/p>\n<p>\n(<i>$ millions, except per share data, at the rate of \u00a31.000 to $1.2162)<\/i>\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignb bwsinglebottom bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwpadr0 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n<b>June 30, 2022\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwpadr0 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignr\">\n<b>June 30, 2021\u00a0<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nNet cash flows from operating activities\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n63.3\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n4.5\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nNet cash flows used in investing activities\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(133.1)\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n(4.2)\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nNet cash flows from financing activities\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0(3.7)\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n222.3\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Net (decrease)\/increase in cash and cash equivalents<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>(73.5)\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>222.6\u00a0<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Net increase in cash, cash equivalents and short-term bank deposits\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>48.2\u00a0<\/b>\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n<b>222.6\u00a0<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>About Exscientia<\/b>\n<\/p>\n<p>\nExscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.\n<\/p>\n<p>\nExscientia is headquartered in Oxford (England, U.K.), with offices in Vienna (Austria), Dundee (Scotland, U.K.), Boston (Mass., U.S.), Miami (Fla., U.S.), Cambridge (England, U.K.), and Osaka (Japan).\n<\/p>\n<p>\nFor more information visit us on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.exscientia.ai%2F&amp;esheet=52817622&amp;newsitemid=20220817005681&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.exscientia.ai&amp;index=6&amp;md5=ab7fa3973a0d33638e01d524841fa6fb\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.exscientia.ai<\/a> or follow us on Twitter <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fexscientiaai&amp;esheet=52817622&amp;newsitemid=20220817005681&amp;lan=en-US&amp;anchor=%40exscientiaAI&amp;index=7&amp;md5=e4ad7651593456eadeaca47ff4794819\" rel=\"nofollow noopener\" shape=\"rect\">@exscientiaAI<\/a>.\n<\/p>\n<p>\n<b>Forward-looking statements<\/b>\n<\/p>\n<p>\nThis press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the progress of discovery and development of candidate molecules, and the timing and progress of, and data reported from, clinical trials of Exscientia\u2019s product candidates, and Exscientia\u2019s expectations regarding its projected revenue and cash runway. Any statement describing Exscientia\u2019s goals, plans, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to: the impact that the COVID-19 pandemic could have on the Company\u2019s business, including the scope, progress and expansion of Exscientia\u2019s product development efforts; the initiation, scope and progress of Exscientia\u2019s and its partners\u2019 planned and ongoing pre-clinical studies and clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; the process of discovering, developing and commercialising product candidates that are safe and effective for use as human therapeutics; and the endeavour of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Exscientia\u2019s Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 23, 2022 (File No. 001-40850), and other filings that Exscientia makes with the SEC from time to time (which are available at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sec.gov%2F&amp;esheet=52817622&amp;newsitemid=20220817005681&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.sec.gov%2F&amp;index=8&amp;md5=35360f575370a62f0159d46a5b14aafb\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.sec.gov\/<\/a>), the events and circumstances discussed in such forward-looking statements may not occur, and Exscientia\u2019s actual results could differ materially and adversely from those anticipated or implied thereby. Although Exscientia\u2019s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by the Company. As a result, you are cautioned not to rely on these forward-looking statements.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Investors:<\/b><br \/>Sara Sherman<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#105;&#108;to&#x3a;&#x69;&#x6e;&#118;es&#x74;&#x6f;&#x72;&#115;&#64;e&#x78;&#x73;&#x63;&#105;&#101;n&#x74;&#x69;&#x61;&#46;&#97;i\" rel=\"nofollow noopener\" shape=\"rect\">&#105;&#x6e;&#x76;&#101;&#x73;&#x74;o&#x72;&#x73;&#64;&#101;&#x78;s&#99;&#x69;e&#110;&#x74;i&#97;&#x2e;a&#105;<\/a><\/p>\n<p><b>Media:<\/b><br \/>Amanda Galgay<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#105;&#108;to&#x3a;&#x6d;&#x65;&#100;ia&#x40;&#x65;&#x78;&#115;&#99;i&#x65;&#x6e;&#x74;&#105;&#97;&#46;&#x61;&#x69;\" rel=\"nofollow noopener\" shape=\"rect\">&#x6d;&#101;&#100;i&#x61;&#x40;&#101;x&#x73;&#x63;&#105;en&#x74;&#105;&#97;&#46;&#x61;&#x69;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>OXFORD, England&#8211;(BUSINESS WIRE)&#8211;Exscientia plc (Nasdaq: EXAI) Recent developments in the Company\u2019s pipeline, collaborations, and operations, as well as financial results for the second quarter and first half 2022, are summarised below. In addition, Exscientia will host a conference call Thursday, August 18 at 1:30 p.m. BST \/ 8:30 a.m. ET to provide an overview of &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/exscientia-business-update-for-second-quarter-and-first-half-2022\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47413","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Exscientia Business Update for Second Quarter and First Half 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/exscientia-business-update-for-second-quarter-and-first-half-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exscientia Business Update for Second Quarter and First Half 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"OXFORD, England&#8211;(BUSINESS WIRE)&#8211;Exscientia plc (Nasdaq: EXAI) Recent developments in the Company\u2019s pipeline, collaborations, and operations, as well as financial results for the second quarter and first half 2022, are summarised below. In addition, Exscientia will host a conference call Thursday, August 18 at 1:30 p.m. BST \/ 8:30 a.m. ET to provide an overview of ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/exscientia-business-update-for-second-quarter-and-first-half-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-17T20:02:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220817005681\/en\/1547256\/21\/1H_2022_1pager_final2.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-business-update-for-second-quarter-and-first-half-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-business-update-for-second-quarter-and-first-half-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Exscientia Business Update for Second Quarter and First Half 2022\",\"datePublished\":\"2022-08-17T20:02:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-business-update-for-second-quarter-and-first-half-2022\\\/\"},\"wordCount\":2195,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-business-update-for-second-quarter-and-first-half-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220817005681\\\/en\\\/1547256\\\/21\\\/1H_2022_1pager_final2.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-business-update-for-second-quarter-and-first-half-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-business-update-for-second-quarter-and-first-half-2022\\\/\",\"name\":\"Exscientia Business Update for Second Quarter and First Half 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-business-update-for-second-quarter-and-first-half-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-business-update-for-second-quarter-and-first-half-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220817005681\\\/en\\\/1547256\\\/21\\\/1H_2022_1pager_final2.jpg\",\"datePublished\":\"2022-08-17T20:02:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-business-update-for-second-quarter-and-first-half-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-business-update-for-second-quarter-and-first-half-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-business-update-for-second-quarter-and-first-half-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220817005681\\\/en\\\/1547256\\\/21\\\/1H_2022_1pager_final2.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220817005681\\\/en\\\/1547256\\\/21\\\/1H_2022_1pager_final2.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-business-update-for-second-quarter-and-first-half-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exscientia Business Update for Second Quarter and First Half 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exscientia Business Update for Second Quarter and First Half 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/exscientia-business-update-for-second-quarter-and-first-half-2022\/","og_locale":"en_US","og_type":"article","og_title":"Exscientia Business Update for Second Quarter and First Half 2022 - Pharma Trend","og_description":"OXFORD, England&#8211;(BUSINESS WIRE)&#8211;Exscientia plc (Nasdaq: EXAI) Recent developments in the Company\u2019s pipeline, collaborations, and operations, as well as financial results for the second quarter and first half 2022, are summarised below. In addition, Exscientia will host a conference call Thursday, August 18 at 1:30 p.m. BST \/ 8:30 a.m. ET to provide an overview of ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/exscientia-business-update-for-second-quarter-and-first-half-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-17T20:02:08+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220817005681\/en\/1547256\/21\/1H_2022_1pager_final2.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/exscientia-business-update-for-second-quarter-and-first-half-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/exscientia-business-update-for-second-quarter-and-first-half-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Exscientia Business Update for Second Quarter and First Half 2022","datePublished":"2022-08-17T20:02:08+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/exscientia-business-update-for-second-quarter-and-first-half-2022\/"},"wordCount":2195,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/exscientia-business-update-for-second-quarter-and-first-half-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220817005681\/en\/1547256\/21\/1H_2022_1pager_final2.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/exscientia-business-update-for-second-quarter-and-first-half-2022\/","url":"https:\/\/pharma-trend.com\/en\/exscientia-business-update-for-second-quarter-and-first-half-2022\/","name":"Exscientia Business Update for Second Quarter and First Half 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/exscientia-business-update-for-second-quarter-and-first-half-2022\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/exscientia-business-update-for-second-quarter-and-first-half-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220817005681\/en\/1547256\/21\/1H_2022_1pager_final2.jpg","datePublished":"2022-08-17T20:02:08+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/exscientia-business-update-for-second-quarter-and-first-half-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/exscientia-business-update-for-second-quarter-and-first-half-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/exscientia-business-update-for-second-quarter-and-first-half-2022\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220817005681\/en\/1547256\/21\/1H_2022_1pager_final2.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220817005681\/en\/1547256\/21\/1H_2022_1pager_final2.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/exscientia-business-update-for-second-quarter-and-first-half-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Exscientia Business Update for Second Quarter and First Half 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47413","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47413"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47413\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47413"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47413"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47413"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}